RecruitingNot Applicable

Analytical Validation of Circulating DNA Analysis Methods: Creation of a Control Cohort

France68 participantsStarted 2026-06-30

Plain-language summary

Pilot, prospective, mono-center study conducted in a population of healthy participants (free of cancer) for the analytical validation of circulating DNA analysis methods. The participants are employees of the institution. Their recruitement is carried out via internal posting (intranet and bulletin boards). The study participation will be strictly voluntary and without consequences on the professional situation of the participants.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1 Adult volunteer (≥ 18 y.o.) * 2 Participant free of cancer * 3 Participant belonging to the personnel of Oncopole Claudius Regaud (IUCT-O) institution * 4 Participant affiliated to a Social Health Insurance in France * 5 Participant who received clear and understandable information about the research * 6 Participant who signed an informed consent form before inclusion into the study and before any study specific procedure * 7 Participant who accepts a blood draw in the context of the research * 8 Participant who agrees to be contacted in the event of an incidental finding of a potential genetic abnormality Exclusion Criteria: * 1 Participant presenting with an associated pathology potentially preventing the adequate conduct of the study procedure * 2 Participant presenting with a contra-indication to blood draw * 3 Participant who reports to the investigator team * 4 Participant who has forfeited his/her freedom bu administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Proportion of participants for which no pathogenic mutation has been detected on the MSK-Access panel.

Timeframe: baseline

Trial details

NCT IDNCT07663994

SponsorInstitut Claudius Regaud

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-31

Contact for this trial

Laura KELLER, PhD

0033 5 31 15 52 14 keller.laura@iuct-oncopole.fr

View on ClinicalTrials.gov More Healthy Volunteers (Cancer) trials